Advances in SEMA3F regulation of clinically high-incidence cancers

Abstract

Cancer has become a leading cause of morbidity and mortality in recent years. Its high prevalence has had a severe impact on society. Researchers have achieved fruitful results in the causative factors, pathogenesis, treatment strategies, and cancer prevention. Semaphorin 3F (SEMA3F), a member of the signaling family, was initially reported in the literature to inhibit the growth, invasion, and metastasis of cancer cells in lung cancer. Later studies showed it has cancer-inhibiting effects in malignant tumors such as breast, colorectal, ovarian, oral squamous cell carcinoma, melanoma, and head and neck squamous carcinoma. In contrast, recent studies have reported that SEMA3F is expressed more in hepatocellular carcinoma than in normal tissue and promotes metastasis of hepatocellular carcinoma. We chose lung, breast, colorectal, and hepatocellular carcinomas with high clinical prevalence to review the roles and molecular mechanisms of SEMA3F in these four carcinomas. We concluded with an outlook on clinical interventions for patients targeting SEMA3F.

Keywords

SEMA3F cancer anti-oncogene

1. Introduction

Malignant tumors have a major impact on human health, with a relatively high mortality rate [1, 2]. Therefore, research, prevention, and treatment of malignant tumors have become a global concern. According to the data reported in 2020, China accounts for 24% of new cancer diagnoses and 30% of cancer-related deaths worldwide [3]. Cancer is expected to become the world’s leading cause of death around 2060 [4]. Incidence and mortality rates of lung, breast, liver, and colorectal cancers are among the highest in all studies and reports [1]. Current research on the molecular aspects of these four clinically prevalent cancers is focused on oncogenes and anti-oncogenes [5, 6, 7]. Semaphorin 3F (SEMA3F) was first identified as an anti-oncogene in lung cancer and has since been linked to the growth, invasion, and metastasis of these four clinically prevalent cancers in several studies [8, 9, 10, 11, 12]. It has also been reported that the oncogenic effect of SEMA3F may be related to its receptors, Neuropilins protein and Plexins protein [13, 14]. The article discusses the regulatory role of SEMA3F and related receptors in cancer and their molecular mechanisms.

2. Search strategy

We obtained 1257 records by entering keywords through the electronic database. Duplicate records were removed using EndNote software. Next, we removed articles that were not relevant to the study content by browsing titles and abstracts, and finally included 76 articles by full-text evaluation (Fig. 1).

Figure 1.

Workflow for literature search and study selection.

3. SEMA3F

Semaphorins (SEMAs) were initially proposed as proteins secreted by axons of the central nervous system [15]. However, later studies revealed that these proteins play a role in tumor growth, angiogenesis, and cell metastasis and are involved in immunoreaction [16, 17, 18, 19]. SEMA3 is the only group of secreted proteins among vertebrate signaling proteins and is classified into seven subclasses (A–G). Studies have shown that SEMA3 functions in neuromodulation, tumor microenvironment, cardiovascular development, and bone homeostasis [16, 20, 21, 22, 23, 24]. In addition, SEMA3A inhibits tumor progression by suppressing tumor angiogenesis, such as breast, lung, and prostate cancers [25, 26, 27, 28, 29]. However, studies analyzing clinical samples from patients with rectal and pancreatic cancers have shown that high expression of SEMA3A is associated with poor patient prognosis [30, 31, 32]. SEMA3B has been more frequently studied in lung and breast cancers, where it inhibits tumor progression by inhibiting cancer cells [33, 34]. It has also been reported that SEMA3B has tumor-suppressive effects on gastric and liver cancers [35, 36]. SEMA3C mainly promotes tumor progression, such as promoting the growth of cervical cancer and accelerating the growth, invasion, and metastasis of prostate cancer [37, 38, 39]. In addition, it promotes the invasion of breast and stomach cancer [40, 41] SEMA3D has received less attention in cancer research. SEMA3D binds to membrane associate protein A2 (ANXA2) in pancreatic cancer to promote cancer cell invasion and metastasis [42, 43]. SEMA3E mainly binds to its receptor PlexinD1 to promote cancer progression [44, 45]. For example, SEMA3E-PlexinD1 accelerates the invasion and metastasis of colorectal cancer, endometrial cancer, and the proliferation and metastasis of gastric cancer [46, 47, 48]. SEMA3G has been little studied in cancer and has been reported to inhibit the metastasis and invasion of glioma cells [49]. SEMA3F, a member of class III signaling, has been widely recognized for its antitumor effects and was first reported to inhibit lung cancer progression as an antitumor factor that inhibits tumor cell growth and metastasis by competing with VEGF for the binding of NRP2 [50, 51, 52]. What’s more, in a later study of clinical samples, SEMA3F expression was reduced in patients with lung, breast, colorectal, prostate cancer, and osteosarcoma and often had a poor prognosis [9, 53, 54, 55, 56]. Its role in inhibiting tumor progression has also been found in recent studies of oral squamous cell carcinoma, esophageal squamous carcinoma, and head and neck squamous carcinoma [57, 58, 59]. In vitro studies have shown that SEMA3F inhibits lung, breast, and colorectal cancer growth, invasion, and metastasis by various mechanisms [12, 51, 60, 61, 62, 63]. After summarizing the in vivo and in vitro studies, we found that SEMA3F inhibited the progression of the lung, breast, and colorectal cancers and could be used as an anti-oncogene to focus our research. In contrast, a recent study showed that SEMA3F promotes metastasis of cancer cells in hepatocellular carcinoma [11]. Hence, further research into the specific regulatory mechanisms of SEMA3F in lung, breast, colorectal, and hepatocellular carcinomas is warranted.

4. SEMA3F-related receptors

Neuropilins include NRP1 and NRP2, a transmembrane protein originally reported as a mediator of axon guidance in the signaling family [64, 65]. NRP1 is located on chromosome 10 and NRP2 on chromosome 2 [66] closely related to angiogenesis, tumor growth, and viral transmission [67, 68, 69, 70]. NRP, as a receptor, can bind to the signaling family and the angiogenic factor VEGF family [71, 72, 73]. The SEMA3F-specific binding receptors are mainly NRP2 [74]. Recently, it was found that the binding of NRP as a receptor with VEGF can promote tumor angiogenesis, while NRP2 and SEMA3F can prevent tumor angiogenesis [18, 75]. In addition, SEMA3F is an inhibitory ligand for NRP2, which regulates NRP2 expression [76, 77]. The reduced expression of NRP2 reduces its ability to bind to VEGF, further preventing tumor angiogenesis.

Plexins are a large class of transmembrane proteins whose family consists of nine members (A1, A2, A3, A4, B1, B2, B3, C1, and D1) [78]. It is reported to be the only known transmembrane receptor that interacts directly with small intracellular GTPases [79]. Plexins are surface receptors of SEMA, and their binding is related to cell adhesion and migration. Except for SEMA3E, which binds directly to plexins, all other members of the SEMA3 family are known to bind first to Neuropilins, which then bind to PlexinA or PlexinD to form a complex [21]. The molecular mechanism of the biological function of SEMA3F as an anti-cancer gene is the SEMA3F/NRP2/PlexinA complex, in which NRP2 acts as a binding receptor and PlexinA as a signal transduction element [13, 14].

5. SEMA3F may suppress lung cancer growth, metastasis and invasion

Lung cancer is the leading cancer with a high risk and death rate [1, 80]. Initially, a high frequency of 3p21.3 deletion was found in the early stage of lung cancer patients. Further studies revealed that this deletion sequence had a high tumor suppressive effect, and a related fragment was isolated from lung cancer strains and named SEMA3F [81]. Next, we investigated the expression of SEMA3F in lung tissues and found that SEMA3F was expressed in normal human lung tissues in the cytoplasmic membrane and cytoplasm. However, it was only expressed in the cytoplasm of cells in lung cancer tissues, and its expression was reduced. This low expression in lung cancer tissues was often associated with the high aggressiveness of the tumor [82, 83]. Also, in clinical samples, elevated expression of NER and VEGF was found in tissues with low SEMA3F expression [83, 84]. At the same time, NRP is a co-receptor for SEMA3F and VEGF [85]. The combination of SEMA3F and NRP inhibits the expression of VEGF, thereby suppressing angiogenesis and inhibiting tumor proliferation. In addition, H157 cells (non-small cell lung cancer cells) stably expressing SEMA3F and H157 cells not expressing SEMA3F were injected into the lungs of mice, and its showed that the survival days of mice injected with cancer cells stably expressing SEMA3F were significantly greater than that of mice without SEMA3F expression [8]. These findings demonstrate that SEMA3F inhibits the progression of lung cancer and improves the prognosis of patients.

At the molecular level, the results show that SEMA3F can down-regulate integrin levels [8]. There is a consensus that integrins promote cancer development by multiple mechanisms, accelerating cell migration and invasion, leading to accelerated progression of many cancers [86, 87, 88]. In addition, integrins can also promote VEGF expression, accelerate angiogenesis, and lead to tumor cell proliferation [89, 90]. The decrease in integrin levels undoubtedly plays a key role in inhibiting lung cancer progression.

In lung cancer signal transduction, SEMA3F attenuates integrin ligase (ILK), leading to decreased phosphorylation of ERK and decreased phosphorylation of AKT, leading to decreased AKT/HIF-1 $\alpha$ /VEGF pathway [8, 51]. The RAS-RAF-MEK-ERK signaling axis, a signaling modality of the MAPK pathway, regulates physiological processes such as cell proliferation, growth, and differentiation [91, 92]. It is therefore considered an important pathway for tumor suppression. ERK protein activation into the nucleus can activate several nuclear transcription factors such as c-FOS, c-jun, ELK-1, c-myc, and ATF2 to regulate cell proliferation and differentiation. SEMA3F inhibits the phosphorylation of ERK and thus inhibits cancer proliferation and growth. In addition, ERK protein activation during tumor progression promotes tumor invasion and metastasis [93, 94]. Therefore, blocking ERK protein activation by SEMA3F in lung cancer improves the prognosis of patients. SEMA3F attenuates the AKT/HIF-1 $\alpha$ /VEGF signaling axis in lung cancer, ultimately leading to decreased expression of VEGF, which acts as a pro-angiogenic factor followed by inhibition of tumor vascular growth and cancer cell proliferation. In addition, it has been reported that PI3K/AKT has the function of upregulating integrin expression [87, 95]. As described previously, the diminished phosphorylation of AKT results in decreased integrin levels, which inhibits tumor progression.

It was reported that ZEB-1 could suppress SEMA3F expression in lung cancer cells by directly binding to the conserved E-box site at the 5’ end of the gene [96]. Zinc finger E box binding homology box (ZEB)-1 is a major transcriptional repressor of E-cadherin in cancer [97, 98]. E-cadherin plays a crucial role in inhibiting cancer cell metastasis by enhancing intercellular adhesion and reducing the metastasis of cancer cells. In addition, loss of E-cadherin is a significant feature of tumor mesenchymal-epithelial transition (EMT), which plays a key role in tumor invasion and metastasis by enhancing cell motility and aggressiveness [99]. ZEB-1 inhibits the expression of E-cadherin, which accelerates the metastasis and invasion of cancer, and SEMA3F, which accelerates the progression of lung cancer. These findings suggest that ZEB-1 could be a promising therapeutic target in future lung cancer research and development.

In conclusion, previous study results demonstrate that SEMA3F has a strong tumor-suppressive effect on lung cancer from several aspects [8, 51]. Furthermore, it can inhibit lung cancer growth, metastasis, and invasion. This prompts us to consider SEMA3F a key breakthrough point in basic and clinical research and targeted drug development in lung cancer. SEMA3F can also be considered a diagnostic and monitoring indicator in diagnosing and managing lung cancer. Of course, the previous results are rigorous and plausible, but constructing a knockout mouse model of SEMA3F may round out the study.

6. SEMA3F may suppress breast cancer growth, metastasis and invasion

As one of the most dangerous diseases for women’s health [100, 101], studying the therapeutic targets of breast cancer is particularly important. The role of SEMA3F as an anti-oncogene was first reported in lung cancer [81]. Later studies reported a high frequency of deletion in the 3p21.3 region in breast cancer patients and demonstrated the presence of SEMA3F in the deletion region [102] suggesting that SEMA3F may also have an anti-oncogenic role in breast cancer. In in vitro cellular assays, the results showed that SEMA3F significantly inhibited the ability of breast cancer cells to move and spread, leading to a decrease in the migration ability of cancer cells [63, 103] and we also demonstrated that SEMA3F inhibited the invasion of breast cancer cells [12]. Furthermore, in a later study of SEMA3F and its receptors in mammary hyperplasia, mammary carcinoma in situ, and invasive mammary carcinoma, it was discovered that the expression of SEMA3F. Its receptors Plexin-A1 and Plexin-A3 in the epithelium decreased with the severity of the lesion, and NRP1 decreased in invasive carcinoma, while NRP2 did not change [54]. Based on the above in vivo and ex vivo findings, we confirmed that SEMA3F inhibited cancer progression in breast cancer. It could inhibit the growth, metastasis, and invasion of cancer cells. Therefore, increasing the expression of SEMA3F could improve the prognosis of patients.

A mechanistic study found that retinoid orphan nuclear receptor alpha (ROR $\alpha)$ , a transcription factor of SEMA3F, could increase the expression of SEMA3F to suppress breast cancer invasion and that SEMA3F downregulation enhanced MEK phosphorylation [12]. ROR $\alpha$ , a member of the orphan nuclear factor family, has shown anti-oncogenic activity in colorectal, hepatocellular, prostate, and ovarian cancers [104, 105, 106, 107]. ROR $\alpha$ -SEMA3F, as a signaling axis, inhibits breast cancer metastasis attributed to diminished MEK phosphorylation. Weakening of MEK, the upstream of ERK, leads to a weakening of ERK phosphorylation, inhibiting tumor development. Studying the relationship between SEMA3F and cancer by studying SEMA3F’s upstream regulators provides a more comprehensive understanding of SEMA3F’s role in cancer and encourages us to study SEMA3F as an anti-oncogene.

Previous studies have shown that SEMA3F binds specifically to the receptor NRP2 to inhibit cancer progression. While in breast cancer studies, SEMA3F was also found to bind to NRP1 to exert anti-cancer effects [103]. It has become a consensus that NRP1 activation in breast cancer promotes cancer growth, metastasis, and invasion. NPR1 is an independent marker of poor prognosis in breast cancer patients [108]. Its activation promotes MAPK pathway and NF- $\kappa$ B pathway signaling, enhances mesenchymal-epithelial transition (EMT), and activates TGF- $\beta$ to accelerate breast cancer progression [109, 110, 111]. The VEGF-NRP1 axis mediates this series of responses that promote breast carcinogenesis, and the combination of SEMA3F and NPR1 competitively inhibits the malignant responses brought about by the VEGF-NRP1 axis in breast cancer patients, thereby inhibiting the progression of breast cancer.

7. SEMA3F may suppress colorectal cancer growth, metastasis and invasion

In recent years, the prevalence of colorectal cancer has been increasing year by year due to the great abundance of material resources and the complexity of dietary behavior of the population [112, 113, 114]. Similarly, the tumor suppressive effect of SEMA3F exists in colorectal cancer, where it specifically binds to NRP2 to inhibit tumor growth and metastasis [60]. Notably, in studies using lung and colorectal cancer cell lines, SEMA3F was a target gene of p53, which negatively regulates tumor angiogenesis through the SEMA3F-NRP2 pathway [61] P53, a key anti-oncogene, has been studied and reported since its discovery to induce cell cycle arrest, apoptosis, and DNA repair [115]. SEMA3F acts as a target gene of p53 against tumor angiogenesis which is valuable in inhibiting tumor progression and improving patient prognosis. Furthermore, it has been demonstrated that NRP2 induces lymphangiogenesis in the colorectum without SEMA3F by activating integrin $\alpha$ 9 $\beta$ 1, thereby accelerating cancer cell metastasis. Overexpression of SEMA3F can downregulate the expression of NRP2 to reduce lymphangiogenesis in colorectal cancer [77]. Lymphatic metastasis is one of the pathways of colorectal cancer metastasis, and tumor lymphatic vessel production inhibition plays a key role in treating metastatic colorectal cancer.

Table 1
SEMA3F regulates information table in breast, lung, colorectal and hepatocellular carcinomas

Type	Function	Mechanism		Ref.
		Common complex	Signal pathway
Breast	Inhibit growth, metastasis, invasion	SEMA3F/NRP12/PlexinA	ROR $\alpha$ -SEMA3F inhibit MEK-ERK pathway	[12, 54, 63, 102, 103]
Lung	Inhibit growth, metastasis, invasion	SEMA3F/NRP2/PlexinA	SEMA3F inhibit ILK/ERK and AKT-STAT3 pathway SEMA3F inhibit E-cadherin and integrins SEMA3F inhibit AKT/HIF-1 $\alpha$ /VEGF	[8, 51, 81, 82, 83, 84, 96]
Colorectal	Inhibit growth, metastasis, invasion	SEMA3F/NRP2/PlexinA	SEMA3F suppress PI3K-AKT/ ASCL2- CXCR4 Pathway SEMA3F suppress GTP-Rac1	[9, 60, 61, 123]
Hepatocellular	Promote metastasis, invasion	_	SEMA3F/LAMA1 activation focal adhesion pathway	[11, 133, 134, 135]

Figure 2.

Mechanism diagram of SEMA3F regulating breast, lung, colorectal and hepatocellular carcinomas. (Created with BioRender.com).

The mechanism of SEMA3F inhibition in colorectal cancer has been revealed. It has been reported that SEMA3F inhibits colorectal invasion and metastasis by downregulating the ASCL2-CXCR4 axis through the PI3K-AKT pathway [9] The transcription factor ASCL2, a regulator of colon cancer progenitor cells, down-regulates the inhibition of colorectal cancer progression, including cancer cell proliferation, metastasis, and invasion [116, 117]. In addition, the chemokine receptor CXCR4 has the property of inducing cancer cell chemotaxis, invasion, and proliferation [118, 119]. ASCL2 can upregulate the expression of CXCR4 in colorectal cancer [120]. Therefore, inhibiting the activity of ASCL2 further inhibits the progression of colorectal cancer. The PI3K-AKT pathway regulates cell proliferation, growth, and metabolism and is commonly and abnormally activated in cancer patients. PI3K or AKT phosphorylation inhibition can inhibit cancer progression [121, 122]. Inhibition of the PI3K/AKT pathway by SEMA3F inhibited cancer progression, while downregulation of PI3K/AKT led to a decrease in ASCL2/CXCR4 expression. This cascade of responses led to a severe inhibition of colorectal cancer progression, which was certainly attributed to SEMA3F. In addition, we have verified in clinical patient specimens that low expression of SEMA3F, high expression of ASCL2, and high expression of CXCR4 in colorectal cancer patients often represent a poor prognosis for the patients [9]. This affirms the presence of SEMA3F as an anti-oncogene in colorectal cancer, providing more options for treating colorectal cancer and a basis for developing targeted therapies.

Modulating the stemness of cancer cells has now become a breakthrough point to inhibit cancer progression. A study claims that SEMA3F can inhibit the stemness of rectal cancer cells by inactivating Rac1 [123]. Stemness of cancer cells means their potency to act as stem cells, having tumorigenic abilities, including independent self-renewal and multi-differentiation [124]. Increased stemness of cancer cells may promote carcinogenesis, metastasis, and invasion, leading to accelerated cancer progression and recurrence [125, 126]. Rac1, a member of the Rho family, is involved in physiological activities such as cell adhesion, proliferation, migration, and motility [127]. Furthermore, Rac1 promotes cancer angiogenesis, invasion, and metastasis [128]. Therefore, inhibition of Rac1 activity by SEMA3F necessarily stops the progression of colorectal cancer. In addition, overexpression of SEMA3F in colorectal cancer cells inhibits the Wnt/ $\beta$ -catenin pathway, while deletion of SEMA3F promotes the Wnt/ $\beta$ -catenin pathway [123]. Wnt/ $\beta$ -catenin enhances the stemness of cancer cells, which has been previously demonstrated [129]. Rac1, an upstream protein of the Wnt/ $\beta$ -catenin pathway, is diminished when Rac1 has inhibited the signaling of the Wnt/ $\beta$ -catenin pathway, leading to decreased stemness of cancer cells, thereby inhibiting cancer progression and improving patient prognosis. In previous reports on breast cancer, it has been investigated that SEMA3F may affect the activation of Rac1 [103]. This suggests that SEMA3F’s regulation of Rac1 is not by chance and that SEMA3F may also play a role in regulating cancer cell stemness. Certainly, the previous results are not sufficient, and more comprehensive experiments on molecular mechanisms may be needed to demonstrate them.

8. SEMA3F may promote hepatocellular carcinoma metastasis and invasion

Hepatocellular carcinoma, one of the most lethal cancers, is often associated with viral hepatitis, alcohol abuse, cirrhosis, and other factors [130, 131, 132]. Antitumorigenic properties of SEMA3F have been reported in various cancers, including lung, breast, and colorectal cancers The role of SEMA3F in hepatocellular carcinoma was rarely reported until recently, when bioinformatics analysis of hepatocellular carcinoma samples revealed that SEMA3F expression was upregulated in hepatocellular carcinoma and that SEMA3F expression was positively correlated with metastasis and pathological stage of patients, and that patients with high SEMA3F expression tended to have a poor prognosis [11, 133, 134, 135]. This is inconsistent with our review of the international literature on SEMA3F as an anti-oncogene for other types of cancer. However, most of these findings are based on bioinformatics analysis, and more basic research is required to prove them. NRP2 acts as an affinity receptor for SEMA3F. In a previous report, NRP2 was highly expressed in cancer tissues, and the results in hepatocellular carcinoma tissues were the same as before [11]. This differs from previous reports that elevated SEMA3F expression can downregulate NRP expression. However, existing research is insufficient to explain the mechanism.

Regarding molecular mechanism, SEMA3F upregulates LAMA1 expression in hepatocellular carcinoma [11]. Laminin alpha 1 (LAMA1) is a major component of the extracellular matrix (ECM), which is involved in metastasis and invasion of cancer cells and promotes cancer development in gastric, colorectal, esophageal, and ovarian cancers [136, 137, 138, 139]. Therefore, activation of LAMA1 expression by SEMA3F in hepatocellular carcinoma accelerates cancer metastasis. This reveals that patients with hepatocellular carcinoma with high SEMA3F expression in clinical practice often have a poor prognosis.

There are very few reports on SEMA3F in hepatocellular carcinoma. Hence, we cannot thoroughly analyze its role and regulatory mechanism, and we hope that more studies will follow. Nevertheless, these few reports are significant and break our original knowledge. Furthermore, SEMA3F does not inhibit tumorigenesis in all tumors, generating new insights for the subsequent research and treatment of hepatocellular carcinoma.

9. Conclusion and prospect

Cancer has affected human health at many levels, causing physical and mental pain to patients and severe economic burdens to families and society. Cancer has clearly become a problem that must be solved for medical progress to continue. We are looking forward to the emergence of more effective treatments. However, we are looking forward to researching targeted drugs at this stage. Targeted therapy is the latest trend in cancer treatment and is emerging as a new treatment strategy that significantly improves the efficiency of cancer treatment and the prognosis of patients. The role of SEMA3F in inhibiting tumor cell growth, invasion, and metastasis exhibited in several malignancies should be of strong interest to us, especially in the lung, breast, and colorectal cancers where the molecular mechanisms are quite well-defined. Although the existing studies cannot fully and concretely explain the mechanism of SEMA3F regulation of tumors, they can be used to develop and test targeted drugs that induce the expression of positive SEMA3F regulators and inhibit the expression of negative regulators, increasing SEMA3F expression. In addition, we can use SEMA3F as a biomarker for clinical diagnosis and patient prognosis assessment by measuring the expression of SEMA3F in tissues or in serum. Notably, most of the existing studies reported that SEMA3F binds to the receptor NRP2 to inhibit tumor angiogenesis, and only in colorectal cancer was SEMA3F mentioned to inhibit cancer lymphangiogenesis. As lymph node metastasis is one of the major pathways of cancer metastasis, we hope that more studies will explore the mechanism of SEMA3F in tumor lymphangiogenesis in depth. Further research and evidence are needed to verify the latest report of SEMA3F promoting tumor progression in hepatocellular carcinoma. Our report summarizes SEMA3F regulation of clinically high-incidence (breast, lung, colorectal, and liver with decreasing incidence order) cancers and their associated molecular mechanisms based on existing research (Fig. 2 and Table 1). Our report may be insufficient, but we look forward to reporting more findings.

Footnotes

Acknowledgments

First and foremost, the authors would like to express their gratitude to all Section colleagues who have investigated and reported on the SEMA3F gene. I appreciate Guangxi Medical University’s Regenerative Medicine Laboratory and my instructors Prof. Qian Liu and Prof. Dezhi Song for providing the research environment.

Conflict of interest

Authors have no conflicts of interest to report.

Author contributions

Conception: Qian Liu.

Interpretation or analysis of data: Chaofeng Wang. Preparation of the manuscript: Chaofeng Wang. Revision for important intellectual content: Qian Huan, Dezhi Song. Supervision: Dezhi Song.

References

Sung

Ferlay

Siegel

R.L.

Laversanne

Soerjomataram

Jemal

and Bray

, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin 71(3) (2021), 209–249.

Lin

Yan

Liu

Yang

and Li

, Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019, Journal of Hematology & Oncology 14(1) (2021), 197.

Cao

Chen

H.D.

Y.W.

and Chen

W.Q.

, Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020, Chin Med J (Engl) 134(7) (2021), 783–791.

Mattiuzzi

and Lippi

, Current Cancer Epidemiology, J Epidemiol Glob Health 9(4) (2019), 217–222.

Markowitz

S.D.

and Bertagnolli

M.M.

, Molecular origins of cancer: Molecular basis of colorectal cancer, The New England Journal of Medicine 361(25) (2009), 2449–60.

Levine

A.J.

, p53: 800 million years of evolution and 40 years of discovery, Nature reviews, Cancer 20(8) (2020), 471–480.

Setton

Zinda

Riaz

Durocher

Zimmermann

Koehler

Reis-Filho

J.S.

and Powell

S.N.

, Synthetic Lethality in Cancer Therapeutics: The Next Generation, Cancer Discovery 11(7) (2021), 1626–1635.

Kusy

Nasarre

Chan

Potiron

Meyronet

Gemmill

R.M.

Constantin

Drabkin

H.A.

Roche

and Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells, Neoplasia 7(5) (2005), 457–65.

Zhou

Z.H.

Rao

Yang

Tan

S.L.

Ding

Zhan

X.G.

Cui

Y.H.

Zhang

Dong

Liu

X.D.

and Bian

X.W.

, SEMA3F prevents metastasis of colorectal cancer by PI3K-AKT-dependent down-regulation of the ASCL2-CXCR4 axis, J Pathol 236(4) (2015), 467–78.

10.

Xue

Wang

Han

Liu

Zhang

Wang

Zhao

and Cui

, The oncogenic role of LncRNA FAM83C-AS1 in colorectal cancer development by epigenetically inhibits SEMA3F via stabilizing EZH2, Aging 12(20) (2020), 20396–20412.

11.

Ouyang

Wang

Yao

and Zhang

, SEMA3F Promotes Liver Hepatocellular Carcinoma Metastasis by Activating Focal Adhesion Pathway, DNA Cell Biol 39(3) (2020), 474–483.

12.

Xiong

Wang

Evers

B.M.

Zhou

B.P.

and Xu

, RORα suppresses breast tumor invasion by inducing SEMA3F expression, Cancer Res 72(7) (2012), 1728–39.

13.

Shiflett

M.W.

Gavin

Tran

T.S.

, Altered hippocampal-dependent memory and motor function in neuropilin 2-deficient mice, Translational Psychiatry 5(3) (2015), e521.

14.

Nakayama

Bruneau

Kochupurakkal

Coma

Briscoe

D.M.

and Klagsbrun

, Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo , Scientific Reports 5 (2015), 11789.

15.

Luo

Raible

and Raper

J.A.

, Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones, Cell 75(2) (1993), 217–27.

16.

Fard

and Tamagnone

, Semaphorins in health and disease, Cytokine & Growth Factor Reviews 57 (2021), 55–63.

17.

Takamatsu

Okuno

and Kumanogoh

, Regulation of immune cell responses by semaphorins and their receptors, Cellular & Molecular Immunology 7(2) (2010), 83–8.

18.

Mastrantonio

You

and Tamagnone

, Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer, Theranostics 11(7) (2021), 3262–3277.

19.

Zhang

C.L.

Hong

C.D.

Wang

H.L.

Chen

A.Q.

Zhou

Y.F.

Wan

Y.N.

and Hu

, The role of semaphorins in small vessels of the eye and brain, Pharmacological Research 160 (2020), 105044.

20.

Toledano

Nir-Zvi

Engelman

Kessler

and Neufeld

, Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression, Int J Mol Sci 20(3) (2019).

21.

Neufeld

and Kessler

, The semaphorins: versatile regulators of tumour progression and tumour angiogenesis, Nature reviews. Cancer 8(8) (2008), 632–45.

22.

van der Klaauw

A.A.

Croizier

Mendes de Oliveira

Stadler

L.K.J.

Park

Kong

Banton

M.C.

Tandon

Hendricks

A.E.

Keogh

J.M.

Riley

S.E.

Papadia

Henning

Bounds

Bochukova

E.G.

Mistry

O’Rahilly

Simerly

R.B.

Minchin

J.E.N.

Barroso

Jones

E.Y.

Bouret

S.G.

and Farooqi

I.S.

, Human Semaphorin 3 Variants Link Melanocortin Circuit Development and Energy Balance, Cell 176(4) (2019), 729–742e18.

23.

Valdembri

Regano

Maione

Giraudo

and Serini

, Class 3 semaphorins in cardiovascular development, Cell Adhesion & Migration 10(6) (2016), 641–651.

24.

Hayashi

Nakashima

Taniguchi

Kodama

Kumanogoh

and Takayanagi

, Osteoprotection by semaphorin 3A, Nature 485(7396) (2012), 69–74.

25.

Maione

Molla

Meda

Latini

Zentilin

Giacca

Seano

Serini

Bussolino

and Giraudo

, Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models, J Clin Invest 119(11) (2009), 3356–72.

26.

Casazza

Laoui

Wenes

Rizzolio

Bassani

Mambretti

Deschoemaeker

Van Ginderachter

J.A.

Tamagnone

and Mazzone

, Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity, Cancer Cell 24(6) (2013), 695–709.

27.

Hanahan

and Folkman

, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell 86(3) (1996), 353–64.

28.

Casazza

Johansson

Capparuccia

Andersson

Giustacchini

Squadrito

M.L.

Venneri

M.A.

Mazzone

Larsson

Carmeliet

De Palma

Naldini

Tamagnone

and Rolny

, Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models, Arteriosclerosis, Thrombosis, and Vascular Biology 31(4) (2011), 741–9.

29.

Luo

Yang

and Zhang

, HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer, International Journal of Biological Macromolecules 222(Pt B) (2022), 2225–2243.

30.

Agesen

T.H.

Sveen

Merok

M.A.

Lind

G.E.

Nesbakken

Skotheim

R.I.

and Lothe

R.A.

, ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis, Gut 61(11) (2012), 1560–7.

31.

Müller

M.W.

Giese

N.A.

Swiercz

J.M.

Ceyhan

G.O.

Esposito

Hinz

Büchler

Giese

Büchler

M.W.

Offermanns

and Friess

, Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer, International Journal of Cancer 121(11) (2007), 2421–33.

32.

Zhang

Klamer

Fernandez

and Li

, A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer, BMC Med Genomics 13(Suppl 5) (2020), 45.

33.

Castro-Rivera

Ran

Thorpe

and Minna

J.D.

, Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect, Proceedings of the National Academy of Sciences of the United States of America 101(31) (2004), 11432–7.

34.

Tomizawa

Sekido

Kondo

Gao

Yokota

Roche

Drabkin

Lerman

M.I.

Gazdar

A.F.

and Minna

J.D.

, Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B, Proceedings of the National Academy of Sciences of the United States of America 98(24) (2001), 13954–9.

35.

Guo

Liang

Liu

Guo

Shen

Liang

and Dong

, MiR-6872 host gene SEMA3B and its antisense lncRNA SEMA3B-AS1 function synergistically to suppress gastric cardia adenocarcinoma progression, Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 22(4) (2019), 705–722.

36.

Zhong

Song

and Zhang

, MiR-718 mediates the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells, Physiological Genomics 51(10) (2019), 500–505.

37.

Liu

Shuai

Luo

and Zhang

, SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis, Front Oncol 9 (2019), 1035.

38.

Hui

D.H.F.

Tam

K.J.

Jiao

I.Z.F.

and Ong

C.J.

, Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers, Int J Mol Sci 20(3) (2019).

39.

Tam

K.J.

Hui

D.H.F.

Lee

W.W.

Dong

Tombe

Jiao

I.Z.F.

Khosravi

Takeuchi

Peacock

J.W.

Ivanova

Moskalev

Gleave

M.E.

Buttyan

Cox

M.E.

and Ong

C.J.

, Semaphorin 3C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells, Scientific Reports 7(1) (2017), 11501.

40.

Peacock

J.W.

Takeuchi

Hayashi

Liu

Tam

K.J.

Al Nakouzi

Khazamipour

Tombe

Dejima

Lee

K.C.

Shiota

Thaper

Lee

W.C.

Hui

D.H.

Kuruma

Ivanova

Yenki

Jiao

I.Z.

Khosravi

Mui

A.L.

Fazli

Zoubeidi

Daugaard

Gleave

M.E.

and Ong

C.J.

, SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1, EMBO Molecular Medicine 10(2) (2018), 219–238.

41.

Miyato

Tsuno

N.H.

and Kitayama

, Semaphorin 3C is involved in the progression of gastric cancer, Cancer Science 103(11) (2012), 1961–6.

42.

Jurcak

N.R.

Rucki

A.A.

Muth

Thompson

Sharma

Ding

Zhu

Eshleman

J.R.

Anders

R.A.

Jaffee

E.M.

Fujiwara

and Zheng

, Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice, Gastroenterology 157(3) (2019), 838–850e6.

43.

Foley

Rucki

A.A.

Xiao

Zhou

Leubner

Kleponis

A.A.

Sharma

Jiang

Anders

R.A.

Iacobuzio-Donahue

C.A.

Hajjar

K.A.

Maitra

Jaffee

E.M.

and Zheng

, Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer, Science Signaling 8(388) (2015), ra77.

44.

Tamagnone

and Rehman

, To die or not to die: Sema3E rules the game, Cancer Cell 24(5) (2013), 564–6.

45.

Klagsbrun

and Shimizu

, Semaphorin 3E, an exception to the rule, J Clin Invest 120(8) (2010), 2658–60.

46.

Tseng

C.H.

Murray

K.D.

Jou

M.F.

Hsu

S.M.

Cheng

H.J.

and Huang

P.H.

, Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer, PLoS One 6(4) (2011), e19396.

47.

Maejima

Tamai

Shiroki

Yokoyama

Shibuya

Nakamura

Yamaguchi

Abue

Oikawa

Noguchi

Miura

Fujiya

Sato

Iijima

Shimosegawa

Tanaka

and Satoh

, Enhanced expression of semaphorin 3E is involved in the gastric cancer development, International Journal of Oncology 49(3) (2016), 887–94.

48.

Hagihara

Haraguchi

Nishimura

Yasueda

Fujino

Ogino

Takahashi

Miyoshi

Uemura

Matsuda

Mizushima

Yamamoto

Mori

Doki

and Eguchi

, PLXND1/SEMA3E Promotes Epithelial-Mesenchymal Transition Partly via the PI3K/AKT-Signaling Pathway and Induces Heterogenity in Colorectal Cancer, Annals of Surgical Oncology 29(12) (2022), 7435–7445.

49.

Zhou

Shi

and Yu

, Effects of SEMA3G on migration and invasion of glioma cells, Oncology Reports 28(1) (2012), 269–75.

50.

Capparuccia

and Tamagnone

, Semaphorin signaling in cancer cells and in cells of the tumor microenvironment – two sides of a coin, J Cell Sci 122(Pt 11) (2009), 1723–36.

51.

Potiron

V.A.

Sharma

Nasarre

Clarhaut

J.A.

Augustin

H.G.

Gemmill

R.M.

Roche

and Drabkin

H.A.

, Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells, Cancer Res 67(18) (2007), 8708–15.

52.

Wei

Tamagnone

and You

, Semaphorins and Their Receptors in Hematological Malignancies, Front Oncol 9 (2019), 382.

53.

Liu

M.H.

W.J.

Cui

Y.H.

Guo

Q.N.

and Zhou

, Downregulation of Semaphorin-3F is associated with poor prognostic significance in osteosarcoma patients, American Journal of Cancer Research 6(10) (2016), 2252–2262.

54.

Staton

C.A.

Shaw

L.A.

Valluru

Hoh

Koay

Cross

S.S.

Reed

M.W.

and Brown

N.J.

, Expression of class 3 semaphorins and their receptors in human breast neoplasia, Histopathology 59(2) (2011), 274–82.

55.

Lantuéjoul

Constantin

Drabkin

Brambilla

Roche

and Brambilla

, Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines, J Pathol 200(3) (2003), 336–47.

56.

Xie

Zhang

Shang

and Su

, SSeCKS/ AKAP12 induces repulsion between human prostate cancer and microvessel endothelial cells through the activation of Semaphorin 3F, Biochemical and Biophysical Research Communications 490(4) (2017), 1394–1398.

57.

Liu

Yin

Ren

and Zhang

, The crucial role of SEMA3F in suppressing the progression of oral squamous cell carcinoma, Cell Mol Biol Lett 22 (2017), 32.

58.

Doçi

C.L.

Mikelis

C.M.

Lionakis

M.S.

Molinolo

A.A.

and Gutkind

J.S.

, Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma, Cancer Res 75(14) (2015), 2937–48.

59.

Zhang

Gao

Sun

Fan

Chen

and Zheng

, Prognostic significance of VEGF-C, semaphorin 3F, and neuropilin-2 expression in oral squamous cell carcinomas and their relationship with lymphangiogenesis, Journal of Surgical Oncology 111(4) (2015), 382–8.

60.

Zhou

Yang

Duan

G.J.

J.J.

Zhang

Pan

Peng

Q.P.

Tan

Ping

Y.F.

Cui

Y.H.

Qian

Yan

X.C.

and Bian

X.W.

, Endogenous axon guiding chemorepulsant semaphorin-3F inhibits the growth and metastasis of colorectal carcinoma, Clin Cancer Res 17(9) (2011), 2702–11.

61.

Futamura

Kamino

Miyamoto

Kitamura

Nakamura

Ohnishi

Masuda

and Arakawa

, Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression, Cancer Res 67(4) (2007), 1451–60.

62.

Nasarre

Gemmill

R.M.

Potiron

V.A.

Roche

Barón

A.E.

Korch

Garrett-Mayer

Lagana

Howe

P.H.

and Drabkin

H.A.

, Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition, Cancer Res 73(23) (2013), 7111–21.

63.

Nasarre

Kusy

Constantin

Castellani

Drabkin

H.A.

Bagnard

and Roche

, Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion, Neoplasia 7(2) (2005), 180–9.

64.

Neufeld

Lange

Varshavsky

and Kessler

, Semaphorin signaling in vascular and tumor biology, Advances in Experimental Medicine and Biology 600 (2007), 118–31.

65.

Niland

and Eble

J.A.

, Neuropilins in the Context of Tumor Vasculature, Int J Mol Sci 20(3) (2019).

66.

Rossignol

Beggs

A.H.

Pierce

E.A.

and Klagsbrun

, Human neuropilin-1 and neuropilin-2 map to 10p12 and 2q34, respectively, Genomics 57(3) (1999), 459–60.

67.

Moutal

Martin

L.F.

Boinon

Gomez

Ran

Zhou

Stratton

H.J.

Cai

Luo

Gonzalez

K.B.

Perez-Miller

Patwardhan

Ibrahim

M.M.

and Khanna

, SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia, Pain 162(1) (2021), 243–252.

68.

Wang

Zhao

Zhang

Shang

and Liang

, Neuropilin-1, a myeloid cell-specific protein, is an inhibitor of HIV-1 infectivity, Proceedings of the National Academy of Sciences of the United States of America 119(2) (2022).

69.

Bry

Kivelä

Leppánen

V.M.

and Alitalo

, Vascular endothelial growth factor-B in physiology and disease, Physiological Reviews 94(3) (2014), 779–94.

70.

Wang

Huang

Zhang

Xing

Xuan

Wang

Huang

Yang

and Tang

, NRP-2 in tumor lymphangiogenesis and lymphatic metastasis, Cancer Lett 418 (2018), 176–184.

71.

Mercurio

A.M.

, VEGF/Neuropilin Signaling in Cancer Stem Cells, Int J Mol Sci 20(3) (2019).

72.

Reichert

Scheid

Roth

Herkel

Petrova

Linden

Weberbauer

Esser

Diehl

Grundmann

Busch

H.J.

Fink

Bode

Moser

and Helbing

, Semaphorin 3F Promotes Transendothelial Migration of Leukocytes in the Inflammatory Response After Survived Cardiac Arrest, Inflammation 42(4) (2019), 1252–1264.

73.

Geretti

Shimizu

and Klagsbrun

, Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis, Angiogenesis 11(1) (2008), 31–9.

74.

Raper

J.A.

, Semaphorins and their receptors in vertebrates and invertebrates, Current Opinion in Neurobiology 10(1) (2000), 88–94.

75.

Soker

Takashima

Miao

H.Q.

Neufeld

and Klagsbrun

, Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor, Cell 92(6) (1998), 735–45.

76.

Chen

Chëdotal

Goodman

C.S.

Tessier-Lavigne

, Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III, Neuron 19(3) (1997), 547–59.

77.

J.J.

Wei

Peng

Zha

Zhou

R.B.

Shi

Zhou

and Liang

H.J.

, Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling, Cancer Lett 358(2) (2015), 200–209.

78.

Angelopoulou

and Piperi

, Emerging role of plexins signaling in glioma progression and therapy, Cancer Lett 414 (2018), 81–87.

79.

Oinuma

Ishikawa

Katoh

and Negishi

, The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras, Science (New York, N.Y.) 305(5685) (2004), 862–5.

80.

Bray

Ferlay

Soerjomataram

Siegel

R.L.

Torre

L.A.

and Jemal

, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin 68(6) (2018), 394–424.

81.

Xiang

R.H.

Hensel

C.H.

Garcia

D.K.

Carlson

H.C.

Kok

Daly

M.C.

Kerbacher

Berg

A. van den

Veldhuis

Buys

C.H.

and Naylor

S.L.

, Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer, Genomics 32(1) (1996), 39–48.

82.

Roche

and Drabkin

H.A.

, The role of semaphorins in lung cancer, Clinical Lung Cancer 3(2) (2001), 145–50.

83.

Brambilla

Constantin

Drabkin

and Roche

, Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration, The American Journal of Pathology 156(3) (2000), 939–50.

84.

Roche

Drabkin

and Brambilla

, Neuropilin and its ligands in normal lung and cancer, Advances in Experimental Medicine and Biology 515 (2002), 103–14.

85.

Gaur

Bielenberg

D.R.

Samuel

Bose

Zhou

Gray

M.J.

Dallas

N.A.

Fan

Xia

and Ellis

L.M.

, Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis, Clin Cancer Res 15(22) (2009), 6763–70.

86.

Cobb

D.A.

de Rossi

Liu

and Lee

D.W.

, Targeting of the alpha(v) beta(3) integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma, Journal for Immunotherapy of Cancer 10(2) (2022).

87.

Sun

Wang

Sun

Gao

Zhang

Sun

Tian

Zhao

Shen

Zhang

and Liu

, Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma, Journal of Experimental & Clinical Cancer Research: CR 38(1) (2019), 449.

88.

Wen

Hou

Yang

Zhao

Qin

Sun

Teng

and Liu

, Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling, Cancer Lett 442 (2019), 320–332.

89.

Reynolds

L.E.

Wyder

Lively

J.C.

Taverna

Robinson

S.D.

Huang

Sheppard

Hynes

R.O.

and Hodivala-Dilke

K.M.

, Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins, Nature Medicine 8(1) (2002), 27–34.

90.

Weis

S.M.

Lindquist

J.N.

Barnes

L.A.

Lutu-Fuga

K.M.

Cui

Wood

M.R.

and Cheresh

D.A.

, Cooperation between VEGF and beta3 integrin during cardiac vascular development, Blood 109(5) (2007), 1962–70.

91.

Sugiura

Satoh

and Takasaki

, ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer, Cells 10(10) (2021).

92.

Ullah

Yin

Snell

A.H.

and Wan

, RAF-MEK-ERK pathway in cancer evolution and treatment, Seminars in Cancer Biology 85 (2022), 123–154.

93.

Shah

Brock

E.J.

and Mattingly

R.R.

, Ras and Rap1: A tale of two GTPases, Seminars in Cancer Biology 54 (2019), 29–39.

94.

Olea-Flores

Zuñiga-Eulogio

M.D.

Mendoza-Catalán

M.A.

Rodríguez-Ruiz

H.A.

Castañeda-Saucedo

Ortuño-Pineda

Padilla-Benavides

and Navarro-Tito

, Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial-Mesenchymal Transition in Cancer, Int J Mol Sci 20(12) (2019).

95.

Shao

Zhang

Wang

and Lin

, Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway, Cancer Lett 364(2) (2015), 165–72.

96.

Clarhaut

Gemmill

R.M.

Potiron

V.A.

Ait-Si-Ali

Imbert

Drabkin

H.A.

and Roche

, ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells, Neoplasia 11(2) (2009), 157–66.

97.

Kakihana

Ohira

Chan

Webster

R.B.

Kato

Drabkin

H.A.

and Gemmill

R.M.

, Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition, Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 4(12) (2009), 1455–65.

98.

Jiang

W.G.

Sanders

A.J.

Katoh

Ungefroren

Gieseler

Prince

Thompson

S.K.

Zollo

Spano

Dhawan

Sliva

Subbarayan

P.R.

Sarkar

Honoki

Fujii

Georgakilas

A.G.

Amedei

Niccolai

Amin

Ashraf

S.S.

Helferich

W.G.

Yang

Boosani

C.S.

Guha

Ciriolo

M.R.

Aquilano

Chen

Azmi

A.S.

Keith

W.N.

Bilsland

Bhakta

Halicka

Nowsheen

Pantano

and Santini

, Tissue invasion and metastasis: Molecular, biological and clinical perspectives, Seminars in Cancer Biology 35(Suppl) (2015), S244–s275.

99.

Cavallaro

and Christofori

, Cell adhesion and signalling by cadherins and Ig-CAMs in cancer, Nature reviews. Cancer 4(2) (2004), 118–32.

100.

Woolston

, Breast cancer, Nature 527(7578) (2015), S101.

101.

Britt

K.L.

Cuzick

and Phillips

K.A.

, Key steps for effective breast cancer prevention, Nature reviews. Cancer 20(8) (2020), 417–436.

102.

Senchenko

V.N.

Liu

Loginov

Bazov

Angeloni

Seryogin

Ermilova

Kazubskaya

Garkavtseva

Zabarovska

V.I.

Kashuba

V.I.

Kisselev

L.L.

Minna

J.D.

Lerman

M.I.

Klein

Braga

E.A.

and Zabarovsky

E.R.

, Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas, Oncogene 23(34) (2004), 5719–28.

103.

Nasarre

Constantin

Rouhaud

Harnois

Raymond

Drabkin

H.A.

Bourmeyster

and Roche

, Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading, Neoplasia 5(1) (2003), 83–92.

104.

Wang

Y.N.

Ruan

D.Y.

Wang

Z.X.

Rong

D.L.

Liu

Z.X.

Wang

J.J.

Jin

Q.N.

H.Y.

Wang

R.H.

and Zeng

Z.L.

, Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc, Oncogene 41(49) (2022), 5266–5278.

105.

Song

Wei

Sun

Tian

and Peng

, Requirement of RORα for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s, Hepatology 75(5) (2022), 1181–1193.

106.

Park

S.C.

Park

I.G.

Kim

and Lee

J.M.

, N-Terminal Domain Mediated Regulation of RORα1 Inhibits Invasive Growth in Prostate Cancer, Int J Mol Sci 20(7) (2019).

107.

Brożyna

A.A.

Kim

T.K.

Zabłocka

Jóźwicki

Yue

Tuckey

R.C.

Jetten

A.M.

and Slominski

A.T.

, Association among Vitamin D, Retinoic Acid-Related Orphan Receptors, and Vitamin D Hydroxyderivatives in Ovarian Cancer, Nutrients 12(11) (2020).

108.

Rachner

T.D.

Kasimir-Bauer

Goebel

Erdmann

Hoffmann

Rauner

Hofbauer

L.C.

Kimmig

and Bittner

A.K.

, Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer, Journal of Cancer Research and Clinical Oncology 147(8) (2021), 2233–2238.

109.

Luo

Hou

Shao

Huang

Meng

Liu

Feng

Xia

Qin

and Zhao

, VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin, Cancer Lett 373(1) (2016), 1–11.

110.

Tang

Y.H.

Rockstroh

Sokolowski

K.A.

Lynam

L.R.

Lehman

Thompson

E.W.

Gregory

P.A.

Nelson

C.C.

Volpert

and Hollier

B.G.

, Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation, Breast Cancer Research: BCR 24(1) (2022), 8.

111.

Zhang

Wang

Shi

Jiang

and Sun

, The miR-124-3p/Neuropilin-1 Axis Contributes to the Proliferation and Metastasis of Triple-Negative Breast Cancer Cells and Co-Activates the TGF-β Pathway, Front Oncol 11 (2021), 654672.

112.

Dekker

Tanis

P.J.

Vleugels

J.L.A.

Kasi

P.M.

and Wallace

M.B.

, Colorectal cancer, Lancet (London, England) 394(10207) (2019), 1467–1480.

113.

Kanth

and Inadomi

J.M.

, Screening and prevention of colorectal cancer, BMJ (Clinical research ed.) 374 (2021), n1855.

114.

Biller

L.H.

and Schrag

, Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review, Jama 325(7) (2021), 669–685.

115.

Engeland

, Cell cycle regulation: p53-p21-RB signaling, Cell Death and Differentiation 29(5) (2022), 946–960.

116.

Shang

Jiang

Ran

Peng

Chen

and Wang

, TET2-BCLAF1 transcription repression complex epigenetically regulates the expression of colorectal cancer gene Ascl2 via methylation of its promoter, The Journal of Biological Chemistry 298(7) (2022), 102095.

117.

Basu

Gavert

Brabletz

and Ben-Ze’ev

, The intestinal stem cell regulating gene ASCL2 is required for L1-mediated colon cancer progression, Cancer Lett 424 (2018), 9–18.

118.

Kang

Siegel

P.M.

Shu

Drobnjak

Kakonen

S.M.

Cordón-Cardo

Guise

T.A.

and Massagué

, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell 3(6) (2003), 537–49.

119.

Teicher

B.A.

and Fricker

S.P.

, CXCL12 (SDF-1)/CXCR4 pathway in cancer, Clin Cancer Res 16(11) (2010), 2927–31.

120.

Dessein

A.F.

Stechly

Jonckheere

Dumont

Monté

Leteurtre

Truant

Pruvot

F.R.

Figeac

Hebbar

Lecellier

C.H.

Lesuffleur

Dessein

Grard

Dejonghe

M.J.

de Launoit

Furuichi

Prévost

Porchet

Gespach

and Huet

, Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells, Cancer Res 70(11) (2010), 4644–54.

121.

Alzahrani

A.S.

, PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside, Seminars in Cancer Biology 59 (2019), 125–132.

122.

Xue

and Li

, Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression, Signal Transduction and Targeted Therapy 6(1) (2021), 400.

123.

Rao

Zhou

Z.H.

Yang

Shi

S.L.

Wang

Ping

Y.F.

Chen

Cui

Y.H.

Zhang

and Bian

X.W.

, Semaphorin-3F suppresses the stemness of colorectal cancer cells by inactivating Rac1, Cancer Lett 358(1) (2015), 76–84.

124.

Valent

Bonnet

De Maria

Lapidot

Copland

Melo

J.V.

Chomienne

Ishikawa

Schuringa

J.J.

Stassi

Huntly

Herrmann

Soulier

Roesch

Schuurhuis

G.J.

Wöhrer

Arock

Zuber

Cerny-Reiterer

Johnsen

H.E.

Andreeff

and Eaves

, Cancer stem cell definitions and terminology: the devil is in the details, Nature reviews. Cancer 12(11) (2012), 767–75.

125.

Milanovic

Fan

D.N.Y.

Belenki

Däbritz

J.H.M.

Zhao

Dörr

J.R.

Dimitrova

Lenze

Monteiro Barbosa

I.A.

Mendoza-Parra

M.A.

Kanashova

Metzner

Pardon

Reimann

Trumpp

Dörken

Zuber

Gronemeyer

Hummel

Dittmar

Lee

and Schmitt

C.A.

, Senescence-associated reprogramming promotes cancer stemness, Nature 553(7686) (2018), 96–100.

126.

Chen

Hsu

W.H.

Han

Xia

and DePinho

R.A.

, Cancer Stemness Meets Immunity: From Mechanism to Therapy, Cell Reports 34(1) (2021), 108597.

127.

Zou

Mao

Yin

Chen

Zhu

Zhou

and Liu

, Emerging roles of RAC1 in treating lung cancer patients, Clinical Genetics 91(4) (2017), 520–528.

128.

Bid

H.K.

Roberts

R.D.

Manchanda

P.K.

and Houghton

P.J.

, RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis, Molecular Cancer Therapeutics 12(10) (2013), 1925–34.

129.

Katoh

and Katoh

, WNT signaling and cancer stemness, Essays in Biochemistry 66(4) (2022), 319–331.

130.

Kulik

and El-Serag

H.B.

, Epidemiology and Management of Hepatocellular Carcinoma, Gastroenterology 156(2) (2019), 477–491e1.

131.

Yang

J.D.

Hainaut

Gores

G.J.

Amadou

Plymoth

and Roberts

L.R.

, A global view of hepatocellular carcinoma: trends, risk, prevention and management, Nature reviews. Gastroenterology & Hepatology 16(10) (2019), 589–604.

132.

Villanueva

, Hepatocellular Carcinoma, The New England Journal of Medicine 380(15) (2019), 1450–1462.

133.

Lou

Wang

Chen

Wang

and Huang

, ncRNAs-mediated high expression of SEMA3F correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma, Molecular therapy. Nucleic Acids 24 (2021), 845–855.

134.

Gao

Zhao

Zhang

Cui

Ren

Yao

and Yang

, Genetic expression and mutational profile analysis in different pathologic stages of hepatocellular carcinoma patients, BMC Cancer 21(1) (2021), 786.

135.

Yang

and Qiu

, Bioinformatics Analysis Using ATAC-seq and RNA-seq for the Identification of 15 Gene Signatures Associated With the Prediction of Prognosis in Hepatocellular Carcinoma, Front Oncol 11 (2021), 726551.

136.

Zhou

P.L.

Zhang

Ren

Zhang

Sun

and Han

, Circular RNA hsa_circ_0000277 sequesters miR-4766-5p to upregulate LAMA1 and promote esophageal carcinoma progression, Cell Death & Disease 12(7) (2021), 676.

137.

and Zhan

, Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer, The EPMA Journal 10(3) (2019), 273–290.

138.

Choi

M.R.

C.H.

Yoo

N.J.

and Lee

S.H.

, Laminin gene LAMB4 is somatically mutated and expressionally altered in gastric and colorectal cancers, APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 123(1) (2015), 65–71.

139.

Zhang

X.Y.

Hou

Zhang

Yue

Jiang

Weissman

S.M.

Pan

B.G.

and Wu

, Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing, Oncogene 36(20) (2017), 2857–2867.

Advances in SEMA3F regulation of clinically high-incidence cancers

Abstract

Keywords

1. Introduction

2. Search strategy

4. SEMA3F-related receptors

5. SEMA3F may suppress lung cancer growth, metastasis and invasion

6. SEMA3F may suppress breast cancer growth, metastasis and invasion

7. SEMA3F may suppress colorectal cancer growth, metastasis and invasion

Table 1 SEMA3F regulates information table in breast, lung, colorectal and hepatocellular carcinomas

9. Conclusion and prospect

Footnotes

Acknowledgments

Conflict of interest

Author contributions

References

Table 1
SEMA3F regulates information table in breast, lung, colorectal and hepatocellular carcinomas